

IL13R α 2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases



R. Alejandro Márquez-Ortiz¹, Maria J. Contreras-Zárate¹, Vesna Tesic¹, Karen L.F. Alvarez-Eraso¹, Gina Kwak¹, Zachary Littrell¹, James C. Costello², Varsha Sreekanth², D. Ryan Ormond³, Sana D. Karam⁴, Peter Kabos⁵, and Diana M. Cittelly¹

ABSTRACT

Purpose: The survival of women with brain metastases (BM) from breast cancer remains very poor, with over 80% dying within a year of their diagnosis. Here, we define the function of IL13R α 2 in outgrowth of breast cancer brain metastases (BCBM) *in vitro* and *in vivo*, and postulate IL13R α 2 as a suitable therapeutic target for BM.

Experimental Design: We performed IHC staining of IL13R α 2 in BCBM to define its prognostic value. Using inducible shRNAs in TNBC and HER2⁺ breast–brain metastatic models, we assessed IL13R α 2 function *in vitro* and *in vivo*. We performed RNAseq and functional studies to define the molecular mechanisms underlying IL13R α 2 function in BCBM.

Results: High IL13R α 2 expression in BCBM predicted worse survival after BM diagnoses. IL13R α 2 was essential for cancer-cell survival, promoting proliferation while repressing invasion.

IL13R α 2 KD resulted in FAK downregulation, repression of cell cycle and proliferation mediators, and upregulation of Ephrin B1 signaling. Ephrin-B1 (i) promoted invasion of BC cells *in vitro*, (ii) marked micrometastasis and invasive fronts in BCBM, and (iii) predicted shorter disease-free survival and BM-free survival (BMFS) in breast primary tumors known to metastasize to the brain. In experimental metastases models, which bypass early tumor invasion, downregulation of IL13R α 2 before or after tumor seeding and brain intravasation decreased BMs, suggesting that IL13R α 2 and the promotion of a proliferative phenotype is critical to BM progression.

Conclusions: Non-genomic phenotypic adaptations at metastatic sites are critical to BM progression and patients' prognosis. This study opens the road to use IL13R α 2 targeting as a therapeutic strategy for BM.

Introduction

Breast cancer brain metastases (BCBM) develop in 15% to 50% of patients with metastatic breast cancer depending on breast cancer subtype. The current treatment options for BM (surgery, radiation, chemo or targeted therapies) have limited success and may worsen neurological function (1). The survival of women with BM from breast cancer remains very poor, and more than 80% will die within a year of their diagnosis (2, 3). Defining the mechanisms underlying metastatic colonization and rapid progression of BM remains an unmet and critical need to identify new therapeutic strategies for these patients.

Despite the substantial progress in defining general mechanisms by which cancer cells in solid tumors acquire the hallmark capability to metastasize (4), the extent to which phenotypic plasticity at metastatic sites contributes to metastatic progression remains poorly understood. Brain metastatic colonization is a relatively rare event in which circulating tumor cells are arrested at brain capillaries, extravasate into the brain parenchyma, survive antitumor effects of brain immunosurveillance cells (microglia and astrocytes), and colonize the brain by growing around existing vessels and adapting to the unique brain microenvironment forming the tumor niche (5–10). This metastatic colonization and adaptation of metastatic cells requires a critically important step, a change between highly invasive phenotypes (for extravasation) to proliferative phenotype (for outgrowth; ref. 11). Many aspects of the phenotypic change leading to tumor progression in the brain metastatic niche remain unknown.

IL13R α 2, a high-affinity receptor for IL-13, is upregulated in several tumors, and studies showed that IL13R α 2 overexpression facilitates the progression and metastasis of various cancer types, including glioblastoma (12–14). In breast cancer, IL13R α 2 mRNA was first identified as upregulated during adaptation to lung and brain metastatic cell lines, and knockdown of IL13R α 2 decreased the metastatic colonization of breast cancer cells into lungs (5, 15). However, the function of IL13R α 2 during brain metastatic colonization and its value as therapeutic target in late brain metastasis remained unexplored. Initially, IL13R α 2 was thought to function mainly as a decoy receptor due to its lack of an intracellular kinase domain (16). However, recent studies show more complex functions for IL13R α 2 in brain tumor progression (17). Thus, here we investigated the clinical value and function of IL13R α 2 protein expression in BM and demonstrate that IL13R α 2 promotes proliferation of disseminated cancer cells and plays a critical role in brain metastatic progression.

¹Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. ²Department of Pharmacology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. ³Department of Neurosurgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. ⁴Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. ⁵Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Diana M. Cittelly, University of Colorado Denver, Anschutz Medical Campus, 12801 East 17th Avenue MS8104, Aurora, CO 80045. E-mail: Diana.Cittelly@cuanschutz.edu

Clin Cancer Res 2021;27:6209–21

doi: 10.1158/1078-0432.CCR-21-0361

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND).

©2021 The Authors; Published by the American Association for Cancer Research

Translational Relevance

The adaptation of disseminated cancer cells to the brain micro-environment involves the transition between invasive phenotype (required for dissemination) to proliferative phenotype (required for outgrowth). Yet, the mediators of this change at metastatic sites remain poorly understood. Here, we provide evidence that upregulation of *IL13R α 2* cells in brain metastases (BM) promotes proliferation and dampens invasion, and knocking down *IL13R α 2* in early and late BM decreases brain metastatic outgrowth. Phase I clinical trials for *IL13R α 2*-targeted chimeric antigen receptors (NCT02208362) have shown initial promise against recurrent multifocal leptomeningeal glioblastoma. Thus, this study provides proof of principle that emerging therapies targeting *IL13R α 2* have the potential to benefit patients with breast cancer BM. Finally, levels of *IL13R α 2* protein expression in the brain—but not mRNA expression levels at primary tumors—predicted worse survival following the diagnosis of BMs. Thus, interrogating non-genomic phenotypic adaptations at metastatic sites has the potential to provide novel therapeutic targets for BMs.

Materials and Methods

Human-derived BM

De-identified human BM samples ($N = 96$) were obtained from archival paraffin-embedded tissue from consenting breast cancer patient-donors, under approved IRB protocols at the University of Colorado.

Cell lines

Triple-negative brain trophic cells 231BR (cells that colonize the brain at high frequency, derived from MDA-MB-231 cells, a kind gift from Dr. Patricia Steeg, Center for Cancer Research, National Cancer Institute) and HER2⁺ brain trophic JmT1BR3 (derived from JMT1 cell line) were cultured in DMEM high glucose supplemented with 10% of FBS and penicillin–streptomycin (P/S). ER⁺HER2⁺ BT474 cells (parental BT474m1 and brain-trophic derivative BT474m1BR, a kind gift of Dr. Dihua Yu, MD Anderson Cancer Center, Houston, Texas) cells were cultured in DMEM/F12 supplemented with 10% of FBS and P/S. Cell lines were free of *Mycoplasma* (MycoAlert™ PLUS-Lonza) and identity of human cells were validated within 6 months of receipt by STR analysis (University of Colorado Tissue Culture Core).

shRNAs and sgRNAs

shRNAs targeting human *IL13RA2*, *EPHB1*, and *EFNB1* (Supplementary Table S1) and non-targeting controls in the pLKO1 vector (RRID:Addgene_27368) were purchased from the Sigma MISSION(R) TRC library through the Functional Genomics Facility at the University of Colorado Cancer Center. Lentiviral doxycycline-inducible systems to overexpress *IL13RA2* with a hemagglutinin tag (HA) or to express *IL13RA2*-targeting shRNAs, were built using pTripz Sox4.965 vector (RRID:Addgene_101120). Briefly, the 21-base shRNAs targeting human *IL13RA2* from two MISSION shRNA Library vectors (sh*IL13RA2*-1 and sh*IL13RA2*-2, Supplementary Table S1) were used to design sense and antisense 110-base oligonucleotides flanked by cohesive ends with XhoI and EcoRI restriction sites, according to the protocol described by Chang and colleagues (18). These sequences were cloned in pTripz Sox4.965 vector (Supplementary Table S2) and verified by sequencing. For *IL13R α 2* overexpress-

sion, full sequence human *IL13RA2* cDNA was amplified from JmT1BR3 cells, flanked at the 3'-end with the sequence encoding an HA-tag, and cloned in the pTripz Sox4.965 vector. Lentiviral particles were produced in HEK 293T cells (RRID: CVCL_1926). Breast cancer cells were transduced for 48 hours and selected using puromycin or cell sorting. When indicated, clonal populations were isolated using the serial dilution method (19).

In a subset of experiments, *IL13RA2* was knocked out using a CRISPR-Cas9 approach (sg*IL13RA2*). For this, a guide-sequence (sg) targeting *IL13RA2* Exon 3 (Supplementary Table S2) was cloned in the SpCas9 plasmid px459 v2.0 (RRID:Addgene_62988) and transfected in 231BR cells. Clonal populations expressing sgEV or sg*IL13RA2* were selected by puromycin resistance and validated by qRT-PCR and WB.

IHC and immunofluorescence

For IHC, heat immobilized deparaffinized primary tumors or BM sections were incubated with 10 mmol/L Citrate buffer (pH 6.0) at 125°C and 25 psi for 10 minutes. After antigen retrieval, endogenous peroxidase was blocked with 3% H₂O₂ in PBS and tissue was blocked with 10% normal horse serum in TBST. Slides were incubated overnight with antibodies for *IL13R α 2* or ephrin B1 (Supplementary Table S3), and AP-anti-Goat IgG and horseradish peroxidase (HRP)-anti-Mouse IgG (ImmPRESS) followed by AP or HRP substrates were used as appropriate. For immunofluorescence studies, fresh-frozen OCT-embedded brain tissues were sectioned at 10- μ m thickness, fixed with methanol–acetone and blocked with 10% normal donkey serum in TBST, and incubated with antibodies against p-FAK, ephrin B, and fluorescently labeled secondary antibodies as indicated (Supplementary Table S3).

qRT-PCR

Total RNA from cultured cell lines was isolated using TRizol according to manufacturer instructions. cDNA was synthesized using the Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Inc.). Primers used for amplification of *IL13RA2*, *EFNB1*, and *EPHB1* are described in Supplementary Table S2. Human *RPL0* gene expressions or mouse β -actin were used as normalization controls. Relative gene expression was calculated using the 2^{- $\Delta\Delta$ C_t} method.

Western blot

Total protein was collected using RIPA buffer (cOmplete Protease Inhibitor Cocktail, PhosSTOP Phosphatase inhibitor, 100 mmol/L Na₃VO₄ and 1 mol/L NaF). Extracts were sonicated (5 pulses, 1 second each pulse, using 20% amplitude) and centrifuged at 7,000 rpm, at 4°C for 10 minutes. Supernatant was collected and total protein was quantified using the DC Protein Assay (Bio-Rad). Protein extracts were denatured in 1X Laemmli Buffer at 95°C for 5 minutes. Proteins were separated in 10% SDS-PAGE and transferred overnight at 25 V to 0.45- μ m PVDF membranes. Antibodies used for western blot are listed in Supplementary Table S3. Immunoreactive bands were acquired using a Li-COR Odyssey CLx and analyzed using Image Studio Software V5.2.

Proliferation assays

Cells were plated (1,000–3,000 cells/well) on 96-well plates and treated with vehicle or 1 μ g/mL doxycycline as indicated. Treatments were performed in 6-replicates in at least two independent experiments. Proliferation was measured using IncuCyte live Imaging (Essen Bioscience) using the percentage of confluence in the phase-channel or total red object area (μ m²/Image) in red-fluorescent channel as readouts. When indicated, data were normalized to time 0 and reported as fold-changes.

BrdUrd incorporation and cell cycle analysis

Cells were plated in 4 replicates (250K cells/plate) and incubated 36 hours in regular media, and experiments repeated at least twice. Cells were then incubated with 15 μ mol/L BrdUrd for 1–2 hours (231BR and BT474, respectively), and BrdUrd incorporation measured using flow cytometry. Briefly, BrdUrd was removed, cells washed with PBS and fixed with 70% ethanol, DNA was denatured with HCl 2 N/0.5% Triton X-100 and incorporated BrdUrd was detected using rat anti-BrdUrd followed by anti-rat-DyLight 488 antibodies (Supplementary Table S3). The percentage of BrdUrd-positive cells and cell-cycle analysis was performed using Gallios Flow Cytometer with Kaluza Analysis Software (Beckman Coulter, Inc.). BrdUrd incorporation was also measured using IF-BrdUrd labeling on slides from mice treated with BrdUrd 2 hours before euthanasia. The percentage of BrdUrd⁺ cells per BM was tabulated from individual metastases in sections from 4 different mice per group.

Matrigel-filled scratch-wound invasion assays

Cells were plated (35,000 cells/well) in 5% Charcoal Stripped FBS in regular media, on 96-well Essen ImageLock plates. Adherent cells were serum-starved for 6 hours and a scratch wound was made using a 96-pin WoundMaker (Essen Bioscience), and wounds were filled with Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix (Corning). Wound images were taken every 4 hours for 24 hours and the relative wound confluency was calculated at each time point using an IncuCyte S3 System (Essen BioScience). When indicated, cells were pretreated with doxycycline (1 μ g/mL) for 48 hours before scratch wound and during assay. Treatments were performed in 6-replicates, and each experiment repeated at least twice.

Transwell invasion assay

Serum starved 231BR cells (150,000 cells) were seeded in the upper chamber of a Boyden Transwell chamber (Neuro Probe) in 500 μ L of serum-free media, separated from the chemoattractant (10% FBS supplemented media) by 8- μ m pore size PCPE-PVP-free membrane (Neuro Probe) coated with growth-factor reduced (GFR) Matrigel (2.5 mg/mL). After 24 hours, cells invading through the lower chamber were collected and quantified using a hemocytometer. Each treatment was done by triplicate in at least two independent experiments. When indicated, cells were pretreated 48 hours with doxycycline (1 μ g/mL).

Invasion in organotypic brain slices

The invasive ability of cells in the brain microenvironment was assessed using organotypic brain slices as we have previously described (20). Other studies have shown that cancer cells invade in all directions into the organotypic brain slices (21). Briefly, 300- μ m coronal brain slices from adult mice were obtained using a VT1000 S vibrating blade microtome (LEICA). Brain slices were plated on 8- μ m pore 12-well/Transwells with 700 μ L of media (MEM/HEPES 50%, horse serum 20%, NaHCO₃ 2 mmol/L, glucose 6.5 mg/mL, glutamine 2 mmol/L and P/S). 231BR and BT474M1 GFP⁺ cancer cells were cultured as mammospheres for 10 days in ultra-low attachment plates, resuspended in serum-free media and plated on top of brain slices (5–20 mammospheres/slice). GFP⁺ spheres were imaged using a fluorescent MVX10 stereo microscope (OLYMPUS) at 0 and 24 hours after plating. Images were exported to ImageJ software (RRID:SCR_003070) and invasion of GFP⁺ cells (green mask) away from the edge of the mammosphere were quantified using Scholl analysis (20, 22).

Experimental BM

Animal studies were approved by University of Colorado Institutional Animal Care and Use Committee. Inducible EV or sh*IL13RA1* 231BR-GFP-luciferase cells (175,000 cells/mouse) were injected in the left ventricle of 8–12-week-old female NSG mice, and mice administered 1 mg/mL doxycycline in 10% sucrose/drinking water: (i) from two days before cell injection, or (ii) 7 days after intracardiac injection. Investigators blinded to the experimental groups performed cell injections and metastasis quantification. Inducible EV or OE-IL13RA2-BT474M1-GFP-luciferase cells (175,000 cells mouse) were injected in 4–16 week NSG mice supplemented with E2-release pellets (1 mg), and mice administered doxycycline from two days before cell injection. Sample size was calculated at 80% power, two-sided tests and $\alpha = 0.05$. Metastatic burden was quantified at day 0, 7, 14, and 19 following intracardiac injection, using IVIS Spectrum *in vivo* imaging system. To assess the proliferative state of BMs, mice were injected intraperitoneally with 10 mg/mL BrdUrd 2 hours before euthanasia. Histological quantification of metastases was performed as previously described (23, 24). Briefly, six hematoxylin and eosin (H&E)-stained serial sections (10- μ m thick), one every 300 μ mol/L in a sagittal plane through the right hemisphere of the brain were analyzed at $\times 4$ magnification using an ocular grid. Every micrometastases (≤ 300 μ mol/L) and metastatic cluster (defined as 4 or more micrometastases together with a > 300 μ m along the longest axis) in each section was tabulated.

Global RNA sequencing and gene expression analysis

Total RNA was collected using TRizol and purified with the RNeasy MinElute Cleanup Kit (Qiagen). Messenger RNA (mRNA) was enriched by oligo dT Selection and cDNA was created by reverse transcription using random primers. cDNA was sequenced using paired-end libraries in the BGISEQ platform to get around 70 million of cleaned 100-base reads per sample. Reads were mapped against the human genome assembly (NCBI assembly accession GCF_000001405.39 and assembly name GRCh38.p13) using hisat2 v2.1.0 (25), and genes differentially expressed between groups (EV vs. sh*IL13RA2*) were determined from the triplicates with Cuffdiff (26) and confirmed with DESeq2 (27). Differentially expressed genes were defined as those genes with logarithmic fold change (logFC) with absolute value greater than 1.5 and *P* value less than 0.05. Normalized expression levels to each sample were calculated using Cuffnorm v2.2.1 (28) and reported as fragments per kilobase of transcript per million mapped fragments (FPKM). GEO# GSE165898. Ingenuity Pathway Analysis (IPA) and GSEA (29) were used to determine canonical pathways significantly altered by downregulation of *IL13RA2*.

Digital imaging

For IF analysis images were collected using a Nikon Eclipse Ti-S inverted microscope or an Olympus MVX fluorescent scope. Minor linear adjustments to brightness and contrast were performed identically and in parallel. IHC slides were scanned using Aperio Scanscope T3 and analyzed using Aperio analysis tool.

Statistical analysis

Statistics were done using GraphPad Prism 9.0.0 software. Two-tailed *t* test, one way ANOVA, repeated measures mixed analysis or repeated measures ANOVA followed by multiple comparisons *post hoc* tests were used as appropriate. When samples did not comply any normality assumption, non-parametric test (Two-tailed Mann-Whitney or Kruskal-Wallis test) were used. For animal

studies, data were normalized to time 0 (fold change) and log-transformed to fit normality assumptions. $P < 0.05$ was considered significant and test assumptions were checked for all analysis. Statistical analysis is reported with each figure legend. Adjusted P values are shown in all graphs.

Results

High IL13R α 2 expression in BCBMs is a predictor of decreased survival

To assess the extent of IL13R α 2 protein expression in late BCBM, we performed IL13R α 2 IHC in a cohort of 96 BCBM and quantified its tumoral expression using Aperio digital pathology. IL13R α 2-positive staining was found in BCBM from Luminal A (ER⁺/PR⁺/HER2⁻, $n = 32$), HER2⁺ ($n = 27$) or TNBC (triple-negative breast cancer, $n = 26$), subtypes (Fig. 1A). Luminal A and HER2⁺ BM showed higher IL13R α 2 expression than TNBC BMs ($P = 0.033$ and $P = 0.043$, respectively). High IL13R α 2 expression (>25% strong positive tumor) predicted for a significantly shorter survival following BM diagnosis in all BCBM ($n = 96$, including 11 cases of unknown BC subtype) compared with those with low IL13R α 2 expression (<25% strong positive tumor; median survival 10 vs. 17.1 months, respectively, $P = 0.0183$, Fig. 1B). High IL13R α 2

expression also predicted poor survival within HER2⁺ BM ($P = 0.027$, Fig. 1C) and TNBC BM ($P = 0.045$, Fig. 1D) but not in luminal BM (where only 2/32 cases with known time-to-death had low IL13R α 2 expression, not shown). Consistent with previously reported expression of IL13R α 2 in brain trophic breast cancer cells derived from TN MDA231, IL13R α 2 expression was found on human cancer cells derived from BCBM (F2-7), and cells that had been selected for their ability to form BM at high frequencies (231BR, JmT1BR, BT474M1BR, Fig. 1E). Interestingly, expression of IL13R α 2 in two BCBM (F2-7, G7-1) was lower when tumors grew as patient-derived xenografts (PDX) in the mammary fat pad of NSG mice (Fig. 1F), suggesting plasticity in the expression of IL13R α 2 in the brain. Together, these data suggest that IL13R α 2 increased expression at late stages of BM progression.

IL13R α 2 promotes proliferation of brain-trophic breast cancer cells

Prior studies have shown opposite roles for *IL13RA2* in breast cancer tumor progression. *IL13RA2* knockdown decreased the ability of lung-trophic MDA231 cells to colonize the lungs without altering primary tumor formation (15, 30). By contrast, independent studies showed that overexpression of *IL13RA2* inhibited tumorigenicity of human breast cancer MDA231 cells (31). To assess the role of *IL13RA2*




Figure 1.

IL13R α 2 expression is high in BM, and increased levels predict worse survival after brain metastasis diagnoses. **A**, IL13R α 2 IHC staining was scored using Aperio Digital Imaging, and tumoral areas with strong intensity scores were considered positive. Graph shows percentage of positive tumor area for a cohort of BM samples from Luminal A ($n = 32$), HER2⁺ ($n = 27$), and TNBC ($n = 26$) breast cancer subtypes. Data were analyzed using ANOVA. Adjusted P value is shown. **B**, All BMs ($n = 96$) were classified as high ($\geq 25\%$ + tumor, blue) versus low IL13R α 2 (<25% + tumor, red), and percentage of survival following BM diagnoses was plotted. **C**, HER2⁺ BMs ($n = 27$) were classified as high or low IL13R α 2 as in **B**. **D**, TNBC BMs ($N = 26$) were classified as high or low IL13R α 2 expression as in **B**. Kaplan-Meier curves (**B-D**) were analyzed using the log-rank test. **E**, WB shows IL13R α 2 expression in breast cancer cells. **F**, The percentage of tumoral area expressing IL13R α 2 in clinical BM (F2-7, G7-1) as compared with the same tumors growing as PDXs in the mammary fat pad (MFP) of NSG mice.




Figure 2. IL13Rα2 promotes proliferation of breast cancer cells. **A**, 231BR and JmT1BR3 cells were transfected with a lentiviral vector expressing the empty vector (EV) or shRNAs targeting *IL13RA2* (sh*IL13RA2*-1 or -2) upstream of Turbo-RFP reporter under doxycycline control. Image shows brightfield and RFP expression after 72 hours treatment with 1 μg/mL doxycycline. **B**, 231BR and JmT1BR3 cells expressing EV or sh*IL13RA2* were treated for 48 hours with vehicle or 1 μg/mL doxycycline. Graph shows *IL13RA2* mRNA levels normalized to GAPDH and relative to WT (veh). **C**, Cells were cultured as in **(B)** for 72 hours, and IL13Rα2 protein expression was assessed by Western blot. GAPDH was used as loading control. Numbers indicate IL13Rα2 fold change relative to vehicle-treated cells. **D**, 231BR and JmT1BR3 cells expressing EV or sh*IL13RA2* were treated with doxycycline (1 μg/mL), and percentage of confluence (for clonal 231BR cells) or Turbo-RFP expression (for pooled JmT1BR3 cells) was measured over time using Incucyte live imaging ($n = 5/6$ treatment). Data analyzed with repeated measures ANOVA followed by multiple comparison *post hoc* corrections. ****, $P < 0.001$ at the last time point. **E**, 231BR cells expressing EV or sh*IL13RA2* were induced with doxycycline for 72 hours then treated with BrdUrd by 1 hour. BrdUrd incorporation (%; left) and cell-cycle analysis by PI (right) were measured by flow cytometry ($n = 4$). Adjusted P values are shown. **F**, Human IL13Rα2 with a hemagglutinin (HA) tag was overexpressed (OE) in a doxycycline inducible system in BT474M1 cells. *IL13RA2* mRNA levels normalized to GAPDH and relative to the vehicle-treated cells (left). WB shows anti-HA and anti-IL13Rα2 (right). Induction with 0.5 μg/mL of doxycycline was allowed by 48 and 96 hours for qRT-PCR and WB, respectively. **G**, BT474M1 EV and OE-*IL13RA2* cells were treated with 0.5 μg/mL of doxycycline and percentage of confluence measured over time as in **D**. Fold change in confluence relative to day 0 ± S.E.M. **H**, DNA replication and cell cycle were determined by BrdUrd (2 hours pulse) and propidium iodide (PI) incorporation in BT474M1 cells as in **(E)**. ****, $P < 0.001$.

in the context of brain metastatic colonization and progression, we used CRISPR/cas9 to knockout *IL13RA2* expression in 231BR cells (Supplementary Fig. S1A). However, stable knockout of *IL13RA2* in multiple cell lines (4T1BR5, 231BR, JMT1BR3) resulted in cell death over passaging or selected clones would emerge with regained expression, suggesting critical roles for *IL13RA2* on cell survival. We reasoned that this survival disadvantage of *IL13RA2* KD cells and emergence of

resistant clones could account for the previously reported discrepancies in IL13Rα2 function in breast cancer.

To address this question, shRNAs targeting *IL13RA2* (sh*IL13RA2*#1 and #2) were cloned downstream of a doxycycline-inducible promoter and linked via an IRES to Turbo-RFP reporter, which allows for transient and time-specific modulation of IL13Rα2 levels. Cells with high IL13Rα2 endogenous expression (231BR, JmT1BR3, **Fig. 1E**)

were transduced with shEV or sh*IL13RA2*, then induced with doxycycline and selected using cell sorting. Doxycycline at the concentration used in these experiments did not affect cell proliferation in parental cells (Supplementary Fig. S1B). 231BR and JmT1BR3 transduced with inducible EV, sh*IL13RA2-1* or sh*IL13RA2* showed strong Turbo-RFP expression as early as 48 hours following induction with doxycycline (Fig. 2A). *IL13RA2* mRNA and protein levels decreased by 50% in 231BR cells and 80% in JmTBR3 cells expressing sh*IL13RA2* within 72 hours following doxycycline induction (Fig. 2B and C). To assess whether IL13R α 2 influenced survival and proliferation of brain trophic cell lines, 231BR or JmT1BR3 cells expressing EV, sh*IL13RA2-1* or sh*IL13RA2-2* were treated with doxycycline and cell confluence was measured over time using live cell imaging (Fig. 2D). In clonal populations of 231BR cells, downregulation of *IL13RA2* decreased cell confluence from 89.1% \pm 2.1% in EV to 66.2% \pm 6.4% in sh*IL13RA2#1* and 75.7% \pm 6.3% in sh*IL13RA2#2* cells ($P < 0.0001$ at 96h). Similarly, in non-clonal JmT1BR3 cells downregulation of *IL13RA2* significantly reduced cell confluence of Turbo-RFP-expressing cells (Fig. 2D). Downregulation of *IL13RA2* decreased the percentage of BrdUrd⁺ cells as compared with EV (39.6 \pm 5.6 in sh*IL13RA2-1* vs. 44.7 \pm 2.1 BrdUrd⁺ cells in EV, respectively, Fig. 2E). sh*IL13RA2* 231BR cells also showed a significant decrease in the percentage of cells in S-phase and an increase in cells arrested in G₁-phase of the cell cycle (Fig. 2E). Together, these data suggest that the survival disadvantage conferred

by *IL13RA2* downregulation results in part from G₁-arrest and decreased proliferation.

To determine whether *IL13RA2* upregulation was sufficient to promote proliferation, an inducible *IL13RA2* overexpression vector was transduced in HER2⁺ breast cancer cells BT474m1 (non-brain trophic parental cells that lack endogenous IL13R α 2, Fig. 1C). Inducible-overexpression (OE) of hemagglutinin-tagged *IL13RA2* (Fig. 2F) significantly increased cell confluence (a 22.6% increase compared with EV by 144 hours $P < 0.0001$; Fig. 2G). Furthermore, *IL13RA2*-OE BT474 cells had an increased percentage of BrdUrd⁺ cells following a 2-hour BrdUrd, a significant decrease in G₁ arrested and an increase in G₂-M cells (Fig. 2H). Taken together, these studies suggest that high levels of IL13R α 2 promote proliferation of breast cancer cells.

IL13RA2 represses invasion of brain-trophic breast cancer cells

Development of BM depends on the ability of disseminated cancer cells to extravasate and colonize the brain parenchyma. To determine whether IL13R α 2 would modulate invasion of brain trophic cells, the invasive ability of EV or sh*IL13RA2* was assessed using a Matrigel-filled scratch-wound assay. Surprisingly, sh*IL13RA2* cells were more invasive as compared with shEV-231BR cells [37.9 \pm 2.5 relative wound confluence (RWC) in EV vs. 59.0 \pm 3.6 RWC in sh*IL13RA2* by 24 hours, $P < 0.0001$; Fig. 3A]. Likewise, downregulation of IL13R α 2 increased the number of cells capable to invade through an 8- μ m pore




Figure 3. High levels of IL13R α 2 repress invasion of BC cells. **A**, 231BR cells expressing EV and sh*IL13RA2* were plated in a confluent monolayer and serum-starved overnight, and a modified Matrigel-filled scratch-wound was used to assess invasion. Left, Graph shows relative wound density (RWD) over time (left). Data analyzed with repeated measures ANOVA followed by multiple comparison *post hoc* corrections. ****, $P < 0.001$ at the last time point. Right, Representative images show invasive front. Blue line marks initial wound-edge. **B**, 231BR serum-starved cells were assessed for their ability to invade through a Matrigel-coated filter (8- μ m pore size) in Boyden chambers. Graph shows number of cells in the lower reservoir after 24 hours. **C**, Invasion assay in organotypic brain slices. 231BR and BT474M1 eGFP⁺ spheres expressing EV, sh*IL13RA2* (for 231BR cells) or OE-*IL13RA2* (for BT474M1 cells) were seeded on top of organotypic brain slices. Edges of spheres were monitored over time by fluorescence microscopy and new intersections to concentric circles determined. Representative images for the same sphere/treatment at 0 and 48 hours are shown. **D**, 231BR EV or sh*IL13RA2* cells were assayed as in **C** and new intersections quantified after 24 hours. Left, Median number of new intersections/sphere in 5- μ m increments from initial sphere edge 24 hours. Right, Total number of new intersections per sphere after 24 hours. **E**, Invasion of BT474M1 EV or OE-*IL13RA2* cells was analyzed as in **D**.

in Matrigel-coated Boyden Chamber assays (Fig. 3B). To assess whether IL13R α 2-modulation of invasion also occurred in the brain extracellular matrix, 231BR cells expressing EV or shIL13RA2 were grown as spheres for 7 days, shRNAs induced with doxycycline for 48 hours and then spheres were plated on top of organotypic brain slices as we previously described (20). Invasion of cancer cells away from the sphere and into the brain slice were measured 24 hours later

and quantified as a function of the formation of new intersections away from the initial sphere edge (Fig. 3C). Downregulation of IL13R α 2 resulted in spheres with an increased number of invasive fronts farther away from the edge (Fig. 3D, left) and significantly more intersections after 24 hours (median # of intersections 24.4 in EV vs. 69.4 in shIL13RA2, $P = 0.01$, Fig. 3D, right). Conversely, upregulation of IL13R α 2 in BT474m1 cells decreased their invasive ability in




Figure 4.

Downregulation of IL13RA2 decreases FAK/SRC but upregulates Ephrin B signaling. **A**, 231BR cells expressing EV or shIL13RA2 were induced with doxycycline for 48 hours, and treated with vehicle or 10 ng/mL human recombinant IL-13 (hrIL-13) in an invasion assay. Graph shows relative wound density (RWD) over time ($n = 6-10$ wells per group), in a modified Matrigel-filled scratch-wound assay. Data analyzed with repeated measures ANOVA followed by multiple comparison *post hoc* corrections. Adjusted P value at last time point *, $P < 0.05$; **, $P < 0.01$. **B**, WB show signaling pathways in 231BR EV or shIL13RA2 cells induced with doxycycline for 72 hours, serum starved overnight, and then treated with 10 ng/mL hrIL-13 for the indicated times. Plot shows quantification of pFAK/FAK and P-SRC/SRC from two independent experiments. **C**, WB shows P-FAK and FAK in BT474.M1 cells expressing EV or OE-IL13RA2, induced with doxycycline for 72 hours and treated with vehicle or 10 ng/mL hrIL-13 for 5 minutes. GAPDH is loading control. **D**, Global RNA sequencing was performed in doxycycline-induced 231BR EV versus 231BR shIL13RA2 cells 48 hours after doxycycline induction ($n = 3$ /group). Volcano plot shows differentially expressed genes in EV versus shIL13RA2 cells. Red dots are genes with $\log_2 FC > 1.5$ and $P < 0.05$. **E**, Ingenuity Pathway Analysis (IPA). The P value (calculated with Fischer's exact test) and Z-score were determined to establish any probable association between our set of genes and a specific pathway. Left, Ephrin B signaling is the only pathway modulated in shIL13RA2 cells with a significant P value and ≥ 2 positive Z-score. Right, The \log_2 -transformed fold change in expression of upregulated genes in the Ephrin B signaling pathway (*KALRN*, *EPHB1*, *CXCR4*, and *EFNB1*). **F**, Relative mRNA expression of EphB1 receptor (*EPHB1*) and ephrin B1-ligand (*EFNB1*) in EV versus shIL13RA2 231BR cells ($n = 3$). **G**, WB shows ephrin B1 expression in 231BR expressing EV or shIL13RA2, and BT474 cells expressing EV or OE-IL13RA2. GAPDH was used as loading control. Numbers show ephrin B1 levels normalized to GAPDH and relative to EV control. **H**, IHC staining of ephrin B1 expression in BCBMs. Representative images of the tumor invasive front in late BM are shown in zoom-in.

organotypic brain slices (Fig. 3E), suggesting a role for IL13R α 2 in repressing the invasive ability of cancer cells *in vitro*. Together, these data suggest a novel and more complex role of IL13R α 2 in modulating phenotypic plasticity of breast cancer cells, with dual roles promoting proliferation while repressing invasion of breast cancer cells.

Downregulation of IL13R α 2 decreases FAK signaling and promotes Ephrin B1 pathway upregulation in cancer cells

Prior studies in colon cancer have shown that stimulation of IL13R α 2 with its cognate ligand IL-13 signals through recruitment and activation of Focal Adhesion Kinase (FAK), SRC and Pi3K/AKT signaling (32). To assess whether similar signaling pathways mediated IL13R α 2 function in breast cancer cells, 231BR and BT474M1 cells expressing sh*IL13RA2* or OE-*IL13RA2* were induced with doxycycline and then treated with IL-13. Stimulation of 231BR EV cells with human IL-13 promoted invasion of cancer cells (Fig. 4A) and led to activation of FAK and SRC (but not AKT or ERK activation; Fig. 4B). However, downregulation of IL13R α 2 alone promoted invasion to levels similar to those induced by IL-13 (Fig. 4A), and resulted in a decrease in FAK and SRC expression and activation even in the absence of ligand (Fig. 4B). Conversely, overexpression of IL13R α 2 in BT474.M1 cells resulted in increased FAK recruitment and activation, even in the absence of IL-13 (Fig. 4C). Given that these cells do not express known IL13R α 2 ligands (IL-13 or putative ligand Chi3L1, as measured by qRT-PCR and RNAseq, *not shown*), these data suggest that upregulation of IL13R α 2 promotes ligand-independent recruitment and activation of FAK/SRC in breast cancer cells.

To further investigate mechanisms downstream of IL13R α 2 that promote proliferation while decreasing invasion, 231BR EV versus 231BR sh*IL13RA2* cells were induced with 1 μ g/mL doxycycline for 96 hours, and global RNA sequencing was performed ($n = 3$ /group). Consistent with the opposite roles of IL13R α 2 in promoting proliferation while repressing invasion, top genes differentially downregulated in sh*IL13RA2* included pro-proliferative *EEF1A2* (Log2FC -4.52 , $P = 0.00005$) and cell cycle and proliferation mediator *CCND2* (Cyclin D2, Log2FC -7.61 , $P = 0.046$). Furthermore, top upregulated genes included well-known invasion mediators *MMP1* (Log2FC 3.2, $P = 0.00005$) and *MMP9* (Log2FC 4.5, $P = 0.0035$; Fig. 4D; Supplementary Table S4A). IPA showed that functions associated with cell migration were upregulated, whereas functions associated with proliferation were repressed in sh*IL13RA2* cells compared with shEV control (Supplementary Fig. S2A). Among pathways differentially regulated among EV and sh*IL13RA2* cells, ephrin B signaling was the top significantly upregulated pathway in sh*IL13RA2* cells with a >2 positive Z-score ($P = 0.0026$; Fig. 4E). Ephrin B signaling is a key axonal guidance molecule during brain development and can play proinvasive and/or pro-proliferative roles in cancer depending on context. Thus, we sought to further determine the extent to which ephrin B1 upregulation contributes to the promotion of invasion and repression of proliferation in BCM. Genes differentially expressed within the Ephrin B signaling pathway included Ephrin Type B-receptor (*EPHB1* and EphB1) and its membrane-bound ligand ephrin B1 (*EFNB1*; Fig. 4E), qRT-PCR confirmed both *EPHB1* and *EFNB1* were significantly upregulated in sh*IL13RA2* cells (Fig. 4F), with *EFNB1* being more abundantly expressed than *EPHB1*. Furthermore, western blot analysis confirmed that downregulation of IL13R α 2 promotes ephrin B1 expression in 231BR cells whereas overexpression of IL13R α 2 downregulates ephrin B1 in BT474 cells (Fig. 4G). Although expression of IL13R α 2 and ephrin B1 proteins are not mutually exclusive in cancer cells or tumors (Fig. 4G), IHC staining of a subset of clinical BM with high levels of IL13R α 2, shows

various degrees of ephrin B1 expression, with smaller cell clusters and invasive fronts showing highest ephrin B1 expression (Fig. 4H). Ephrin B1 was also expressed in endothelial cells in the brain niche. Thus, these data suggest that high ephrin B1 marks a subpopulation of highly invasive tumor cells, whereas high IL13R α 2⁺ preferentially marks highly proliferative cancer cells in BMs.

Ephrin B1 promotes invasion of BCM cells

To assess whether ephrin B1 ligand (*EFNB1*) or EphB1 receptor (*EPHB1*) contributes to increased invasion *in vitro*, two shRNAs were used to downregulate ephrin B1 (sh*EFNB1*-1, 2) or EphB1 receptor (sh*EPHB1*-2; Fig. 5A) in 231BR cells. Partial downregulation of *EFNB1* resulted in a significant decrease in the invasive ability of 231BR cells as measured in a Matrigel-filled scratch-wound assay (Fig. 5B). To assess whether *EFNB1* upregulation was linked to the promotion of invasiveness in the context of IL13R α 2 loss, sh*IL13RA2* were transduced with sh*EFNB1* to prevent *EFNB1* upregulation. Blockage of *EFNB1* in sh*IL13RA2* cells strongly decreased the invasive ability of cancer cell *in vitro* (Fig. 5C). Conversely, forced expression of *EFNB1* in EV cells (which mimics the *EFNB1* upregulation in sh*IL13RA2* cells) significantly increased invasion as compared with shEV cells (Fig. 5D). Despite its lower relative expression, downregulation of *EPHB1* also diminished invasion as compared with EV-expressing cells (Fig. 5E), suggesting that both ephrin B1 ligand and its receptor EphB1 modulate the invasive ability of cancer cells.

Loss of ephrins has a cell type and context-dependent effect on cancer cell proliferation. We therefore assessed whether *EFNB1* or *EPHB1* plays a role in the proliferative ability of breast cancer cells and can explain the phenotypic changes induced by KD of IL13R α 2. Downregulation of *EFNB1* but not *EPHB1* significantly increased the percentage of cells in S and G₂-M, increased the percentage of G₁-arrested cells (Fig. 5F) and increased BrdUrd incorporation (Fig. 5G), suggesting a role for *EFNB1* in repressing the ability of cells to undergo DNA synthesis and replication. However, an increased percentage of cells incorporating DNA and entering the cell cycle did not increase overall cell growth, as long-term analysis showed a significantly decreased confluence of sh*EFNB1* and sh*EPHB1* cells upon 96 hours *in vitro* (Fig. 5H). Together, these data suggest that *EFNB1* expression in breast cancer cells promotes their invasion and survival.

Downregulation of IL13R α 2 decreases BM outgrowth after cancer cell dissemination

Given the observed dual role of IL13R α 2 in promoting proliferation but repressing invasion, we reasoned that upregulation of IL13R α 2 and its promotion of proliferation would be critical for brain metastatic outgrowth and progression and explain the clinical correlation between high IL13R α 2 and worse survival following BM diagnoses. Conversely, downregulation of IL13R α 2 (and/or increases in ephrin B1) would be necessary for cells to invade and be most relevant to early stages of tumor dissemination and early extravasation in the brain. Analysis of a public dataset of primary breast cancer with known development of BM (33) shows that *IL13RA2* mRNA levels in the primary tumor do not predict different outcomes in disease-free survival (DFS) or brain metastases-free survival (BMFS; Supplementary Fig. S3A). However, high levels of *EFNB1* mRNA in the primary tumor predicted a worse DFS ($P = 0.0135$) and BMFS ($P = 0.043$; Supplementary Fig. S3B). Moreover, patients with primary tumors expressing both high *EFNB1*/low *IL13RA2* (predicted to be more invasive) had a worse DFS ($P = 0.0067$) and BMFS ($P = 0.034$) as compared with patients that had both low *EFNB1*/High *IL13RA2* (predicted to be less invasive; Supplementary Fig. S3C). Thus, these




Figure 5. Downregulation of EFNB1 impairs invasion and promotes DNA synthesis. **A**, 231BR cells expressing EV or shRNAs targeting *EFNB1* (sh*EFNB1*-1/2) or *EPHB1* (sh*EPHB1*-1/2) were cultured for 48 hours. *EFNB1* and *EPHB1* mRNA levels were detected by RT-qPCR, normalized to GAPDH, and reported as relative to EV. **B**, 231BR cells expressing EV and sh*EFNB1*-1/2 were plated in a confluent monolayer and serum starved overnight, and a modified Matrigel-filled scratch wound was used to assess invasion. Graph shows relative wound density (RWD) over time ($n = 6-10$ wells per group). Data analyzed with repeated measures ANOVA followed by multiple comparison *post hoc* corrections. **, $P < 0.01$; ****, $P < 0.001$ at the last time point. **C**, 231BR cells expressing EV or sh*IL13RA2* were transfected with shNC or sh*EFNB1* as indicated, and induced with doxycycline for 72 hours before plating. Invasion was measured as in **B**. *, $P < 0.05$; **, $P < 0.01$. **D**, 231BR cells were transfected with a lentiviral empty vector (EV) or overexpressing *EFNB1* gene (OE-*EFNB1*). Left, Graph shows *EFNB1* mRNA levels normalized to GAPDH and relative to EV cells. Right, Graphs show invasion of 231-EV and OE-*EFNB1* analyzed as in **B**. ****, $P < 0.001$ at the last time point. **E**, 231BR cells expressing EV or sh*EPHB1*-1/2 were plated and analyzed for invasion as in **B**. **F**, 231BR cells expressing EV and sh*EFNB1*-1/2 or sh*EPHB1*-1/2 were plated for 48 hours, treated with BrdUrd, 1 hour stained with PI for cell-cycle analysis. Graph shows cell-cycle analysis by flow cytometry ($n = 4$). Adjusted P values are shown. **G**, BrdUrd incorporation measured in cells from **F**. **H**, 231BR cells expressing EV and sh*EFNB1*-1/2 or sh*EPHB1*-1/2 were plated, and percentage of confluence was measured over time using Incucyte live imaging ($n = 5$ wells per treatment). Data analyzed with repeated measures ANOVA followed by multiple comparison *post hoc* corrections. ****, $P < 0.001$ at the last time point.

data suggest that a proinvasive phenotype at the primary site may predict dissemination and seeding to metastatic sites, but the ability to proliferate at distant sites is critical for disseminated cancer cells to outgrowth as metastases.

Because analysis of IL13R α 2 expression in late BMs showed that increased IL13R α 2 predicted worse survival after BMs diagnoses (Fig. 1), we next tested the effect of IL13R α 2 downregulation in the outgrowth of disseminated cancer cells. First, doxycycline-inducible shEV or sh*IL13RA2* 231BR cells expressing luciferase reporter were

injected intracardially in female NSG mice ($N = 10$ /group), and cancer cells were allowed to invade and colonize the brain parenchyma for 7 days. At this time point in this experimental metastases model, cancer cells have extravasated the brain parenchyma and formed micrometastasis (6). Mice were then treated with doxycycline for additional 2 weeks to assess how downregulation of IL13R α 2 would influence late brain metastatic outgrowth. Consistent with its proliferative function in late BM, downregulation of IL13R α 2 resulted in a significant delay in the outgrowth of brain




Figure 6. Downregulation of IL13R α 2 reduces brain metastatic progression. **A**, Female NSG mice were injected intracardially with 175,000 231BR-EV ($n = 10$) or shIL13RA2 cells ($N = 9$) expressing luciferase, and cells were allowed to seed and colonize for 7 days before induction with doxycycline. Brain metastatic burden was measured via *in vivo* imaging immediately after cell injection and the indicated times. Head total flux for each animal was normalized to brain signal at time 0 (Fold Change FC). Left, Graph shows Log-transformed FC \pm SEM over time for EV versus shIL13RA2-injected mice. Blue arrow indicates start point for doxycycline treatment. Normally distributed Log-transformed FC values were analyzed using Repeated Measures Mixed effects. Right, Representative image of brain metastatic burden in mice injected with shEV and shIL13RA2. *******, $P = 0.0007$ at the indicated time point. **B**, Histologic quantification of BMs from mice in **A**. Left, Each dot represents the median number of micrometastases (<300 μ m) per mouse, and the line designates the group median. Right, Each dot represents the total number of metastatic clusters per mouse. Data were analyzed using the Mann-Whitney test. **C**, Female NSG mice were injected as in **A** ($n = 10$ /group), but cells and mice had been pretreated with doxycycline for 2 days before cell injection. Left, Graph shows Log-transformed FC \pm SEM over time for EV versus shIL13RA2 injected mice. Normally distributed Log-transformed FC values were analyzed using Repeated Measures Mixed effects. *****, $P = 0.045$; ******, $P = 0.0052$ at the indicated time points. Right, Representative image of brain metastatic burden in mice injected with shEV and shIL13RA2 in this experiment. **D**, Histologic quantification of BMs for mice in **C** surviving at day 19 ($n = 7$ for EV, $N = 10$ for shIL13RA2). **E**, Representative images of BM in EV versus shIL13RA2 from **A** to **B**. Blue arrows denote BMs with a “less invasive” growth pattern, black arrows BMs with invasive fronts. **F**, Mice from **A** were injected with BrdUrd 2 hours before euthanasia, and BrdUrd incorporation in BMs was quantified by IF. Top, Representative image of BrdUrd staining in macro- and micrometastases from EV versus shIL13RA2 mice. Bottom, Percentage of BrdUrd⁺ cells quantified in individual metastases from four mice with histologically detectable BMs per group. **G**, Double-IF staining of p-FAK (red) and ephrin B1 (green) in BMs from EV versus shIL13RA2 mice. Blue is DAPI.

metastases and reduction of BM burden by 19 days following injection, as measured by IVIS (Fig. 6A). Histological quantification of BM at euthanasia showed that downregulation of IL13R α 2 decreased the median number of micrometastases per mouse brain (<300 μ m, average 14.3 \pm 16.30 in EV vs. 2.5 \pm 4.07 in shIL13RA2,

$P = 0.045$) as well as the total number of metastatic clusters per brain (average 12.8 \pm 12.9 in EV vs. 2.0 \pm 2.6 in shIL13RA2, $P = 0.024$, Fig. 6B).

To assess whether earlier downregulation of IL13R α 2 (and the increase in pro-invasive ephrin B1) would promote—rather than

block—brain metastatic colonization, the experiment was repeated as described, but both cancer cells and mice were pre-treated with doxycycline to ensure downregulation of IL13R α 2 from early stages of brain metastatic colonization (Fig. 6C). No changes in brain metastatic burden were observed at day 7 following intracardiac injection, but shIL13RA2 cells showed a significant decrease in brain metastatic IVIS signal by 14 and 19 days after intracardiac injection. Histological quantification of BMs at euthanasia also showed a significant decrease in the median number of micrometastases (9.0 ± 6.7 in EV vs. 3 ± 3.2 in shIL13RA2, $P = 0.02$) and the total number of metastatic clusters (15.5 ± 4.3 in EV vs. 7.1 ± 4.5 in shIL13RA2, $P = 0.0019$) in shIL13RA2 compared with EV cells at euthanasia (Fig. 6D). To assess whether overexpression of IL13R α 2 in poorly metastatic BT474.M1 cells would be sufficient to promote brain metastatic colonization, doxycycline-induced EV or OE-IL13RA2 cells were injected intracardially in doxycycline-treated NSG mice ($n = 10$ /group) and metastatic outgrowth was measured via IVIS. Albeit an earlier disadvantage for OE-IL13RA2 BT474M1 cells to seed in the brain (possibly due to a decreased invasive ability), there were no differences in brain metastatic progression in EV versus OE-IL13RA2 (Supplementary Fig. S4). Thus, downregulation of IL13R α 2 before or after seeding in the brain decreased brain metastatic colonization and progression of BC cells *in vivo*, but overexpression of IL13R α 2 in a model with poor invasive potential was not sufficient to promote brain metastatic colonization.

We next evaluated the extent to which downregulation of IL13R α 2 in BMs *in vivo*, reflected the phenotypes and signaling pathways identified *in vitro*. Although there are not well-established markers for exclusively labeling invasive breast cancer cells (particularly from basal-like TNBC), BMs from shIL13RA2 cells were generally smaller and showed various invasive fronts (Fig. 6E, black arrows) compared with BMs from shEV cells, which tended to appear as rounded more delimited metastases (Fig. 6E, blue arrows). To quantify the proliferative status of EV versus shIL13RA2 BMs, mice in which IL13R α 2 was induced 7 days after intracardiac injection (from Fig. 6A) were injected with 10 mg/mL BrdUrd 2 hours before euthanasia and the percentage of brain metastatic cancer cells incorporating BrdUrd was quantified by immunofluorescence. Consistent with the decrease in proliferation in shIL13RA2 observed *in vitro*, BM from shIL13RA2 cells showed lower percentage of cancer cells incorporating BrdUrd per metastasis (Fig. 6F). Furthermore, BMs from EV cells (with high levels of IL13R α 2) showed high expression of p-FAK and low expression of ephrin B1, whereas BM from shIL13RA2 cells showed increased expression of ephrin B1 and lacked expression of p-FAK (Fig. 6G). Collectively, these results support the notion that IL13R α 2 promotes proliferation of brain metastatic cells through a mechanism involving activation of FAK signaling and modulation of ephrin B1.

Discussion

An increased invasive ability is better known to impact the ability of cancer cells to move away from primary tumors and seed at metastatic sites (34), but a complete or partial restoration of a more proliferative phenotype has been proposed as critical for the growth of disseminated cancer cells at metastatic sites, particularly BM (35). Here we show that (i) high levels of IL13R α 2 promote proliferation and repress invasion; (ii) high expression of IL13R α 2 protein in BM predicted worse survival after BM diagnosis, and (iii), downregulation of IL13R α 2 decreased brain metastatic burden *in vivo*. These findings support the notion that the ability of cancer cells to acquire (at least temporarily) a less invasive, more epithelial and proliferative phenotype is critical for brain met-

astatic outgrowth. Consistent with prior reports showing upregulation of IL13RA2 in breast cancer cells selected for brain tropism (5), we found high expression of IL13R α 2 in brain metastasis but not in matched primary tumors growing in the mouse mammary fat pad. IL13RA2 mRNA levels in primary tumors do not predict for worse clinical prognosis, further supporting the upregulation of IL13R α 2 as a late event occurring at the site of metastasis, which cannot be predicted by interrogating the primary tumor.

Although our studies did not aim to address the dynamics of IL13R α 2 expression at primary versus metastatic sites, our results suggest a dynamic nature of IL13R α 2 expression similar to other molecular markers such as NDRG1 (36). Using multiphoton laser scanning microscopy, NDRG1 was shown to be critical for the arrest of slow-cycling cells to the brain capillary and the initiation of metastasis, yet loss of NDRG1 promoted the growth of primary tumors in at least one model (36). Similarly, prior studies showed controversial roles for IL13R α 2 as suppressor of tumorigenesis in models of primary breast cancers (31) and a tumor and metastasis promoter in a model of breast to lung metastasis (15). Our results provide an explanation for such discrepancies as sustained inhibition of IL13R α 2 (such as used in these prior studies; refs. 15, 30, 31) resulted in cell death or emergence of resistant phenotypes, and the observed dual role of IL13R α 2 in invasion versus proliferation can differentially influence primary tumor versus metastasis. Nonetheless, our results support a prometastatic function for high levels of IL13R α 2 in late-stage BM and in highly aggressive TNBC and Her2⁺ BC subtypes.

Mechanistically, our findings point to integrin and cell-cell communication as likely triggers for the upregulation of IL13R α 2 and the promotion of proliferation during metastatic progression. Similar to previous findings in colorectal cancers (4, 32), upregulation of IL13R α 2 was accompanied by increased levels of total and activated FAK, and numerous studies have demonstrated a regulatory role for FAK/SRC in cell-cycle progression driven through transcriptional activation of cyclin D1 (37). FAK/integrin signaling is well known to influence epigenetic plasticity. Interestingly, IPA analysis of EV versus shIL13RA2 cells showed KDM3A (a known activator of gene expression through removal of repressive H3K9 histone methyl 1 and 2 marks), as the top transcriptional regulator being activated in cells losing IL13R α 2 (2.06 Activation Z-score, $P = 7.08 \times 10^{-12}$, Supplementary Table S4B). KDM3A has been shown to promote anoikis (38), migration and invasion of breast cancer cells (39), as well as increase of KDM3A in breast cancer cells has been shown to result from loss of integrin/FAK signaling (38). Thus, it is likely that IL13R α 2 promotes proliferation through downstream KDM3A activation.

Our *in vitro* studies demonstrate a ligand-independent function of IL13R α 2 in BM [as we did not observe expression of its high affinity ligand IL-13 (40, 41) or the putative ligand CHI3L1 (42) in human breast cancer cells]. However, we observed increases in FAK/SRC signaling in IL13R α 2-expressing cells in response to IL-13, suggesting that the function of IL13R α 2 is likely to be modulated by heterogeneous expression of IL-13 in cancer cells or local availability of IL-13 in the tumor microenvironment (43). It is unclear to what extent murine IL-13 binds to human IL13R α 2; therefore, our xenograft model may not fully inform how IL-13 or other IL13RA2 ligands contribute to the prometastatic function of IL13R α 2 in the brain. Moreover, IL-13 induced FAK activation in BT474 cells lacking IL13R α 2, indicating that not all IL-13-induced FAK recruitment is dependent on IL13R α 2. Because breast cancer cells have been reported to express the other cognate ligands for IL-13 (IL13RA1 and IL4R; ref. 44), these are likely to contribute to the overall signaling elicited by IL-13 in BC cells.

Further studies are warranted to assess how IL-13/IL13R α 2 dependent signaling may affect the proliferative or invasive function of IL13R α 2.

Knockdown of IL13R α 2 in brain trophic cells increased expression of multiple members of the bidirectional ephrin B signaling pathway, including EphB1 (*EPHB1*, a receptor tyrosine kinase that mediates forward signaling) and ephrin B1 (*EFNB1*, an ephrinB1 transmembrane ligand, which mediates reverse signaling). Ephrin B1 was identified as one of 5 potential biomarkers for brain metastatic cells *in vitro* (45), but their function was not fully elucidated. Ephrin-mediated signaling plays key roles in migration, invasion, and proliferation depending on the cell types and cellular contexts (46, 47). Eph-forward signaling induces cytoskeleton changes via the modulation of integrin expression and function, and the modulation of focal adhesion signaling (46, 48), whereas the activation of ephrin reverse signaling promotes cell polarization and mesenchymal-epithelial transition during development through inactivation of cell division control protein 42 (CDC42; ref. 49). SRC homology 2 (SH2)-adaptor proteins are thought to link Ephs to cytoskeletal and focal adhesion proteins and to facilitate actin cytoskeletal changes by modulating the activity of RHO family proteins (50). Here, we observed that ephrin B1 expressed in small metastatic clusters or invasive fronts of clinical BM, and downregulation of ephrin B1 significantly impaired the invasive ability of breast cancer cells, consistent with a proinvasive role for ephrin B1 in breast cancer cells. Moreover, high ephrin B1 mRNA levels at primary tumors predicted worse DFS and BMFS, supporting the hypothesis that invasive phenotypes are critical for metastatic dissemination. The fact that upregulation of IL13R α 2 in BT474M1 cells (with concomitant downregulation in endogenous ephrin B1 levels) was not sufficient to promote brain colonization in this model, further supports the notion that the ability to invade and extravasate is required for metastatic colonization. Yet, the proliferative ability of cancer cells at the metastatic sites remains a critical driver for late metastatic outgrowth, as downregulation of IL13R α 2 (albeit increasing the invasive ability of cancer cells) was sufficient to decrease brain metastatic progression *in vivo*.

Finally, our findings have important therapeutic implications. Multiple targeted therapies are being developed against IL13R α 2, including bacterial toxins conjugated to IL-13 (51), nanoparticles (52), oncolytic virus (53), as well as immunotherapies using monoclonal antibodies (54), IL13R α 2-pulsed dendritic cells (55), and IL13R α 2-targeted chimeric antigen receptors (56, 57). Phase I clinical trials for IL13R α 2-targeted chimeric antigen receptors (NCT02208362) showed that delivery of IL13R α 2-targeted CAR-T cells into the cerebrospinal fluid was well tolerated and proved effective against

recurrent multifocal leptomeningeal glioblastoma, according to a case report (58). Given our findings that IL13R α 2 is expressed at various levels in all BCBMs and other studies have shown that IL13R α 2 promotes lung metastasis, emerging therapies targeting IL13R α 2 have the potential to benefit patients with brain and lung metastasis.

Authors' Disclosures

M.J. Contreras-Zárate reports grants from U.S Department of Defense during the conduct of the study. S.D. Karam reports grants from Roche and AstraZeneca outside the submitted work. P. Kabos reports grants from NIH during the conduct of the study as well as grants from Eli Lilly, Pfizer, Sanofi, Genentech, AstraZeneca, and Radius Health outside the submitted work. D.M. Cittelly reports grants from Department of Defense Breast Cancer Research Program and NIH/NCI during the conduct of the study. No disclosures were reported by the other authors.

Authors' Contributions

R.A. Márquez-Ortiz: Conceptualization, data curation, formal analysis, validation, writing—original draft, writing—review and editing. **M.J. Contreras-Zárate:** Conceptualization, formal analysis, validation, investigation, writing—review and editing. **V. Tesic:** Investigation. **K.L.F. Alvarez-Eraso:** Validation, investigation. **G. Kwak:** Investigation. **Z. Littrell:** Investigation. **J.C. Costello:** Data curation, formal analysis, writing—review and editing. **V. Srekanth:** Data curation, formal analysis, writing—review and editing. **D.R. Ormond:** Resources, funding acquisition, writing—review and editing. **S.D. Karam:** Conceptualization, investigation, writing—review and editing. **P. Kabos:** Conceptualization, funding acquisition, writing—review and editing. **D.M. Cittelly:** Conceptualization, resources, formal analysis, supervision, funding acquisition, writing—original draft, project administration, writing—review and editing.

Acknowledgments

This work was supported by DoD-BCRP W81XWH-15-1-0352, R37 CA227984, Cancer League of Colorado, and the Metavivor Research Foundation (to D.M. Cittelly). P. Kabos is supported by NIH R01-CA20544. M.J. Contreras-Zárate is supported by DoD BCRP W81XWH-19-1-0033. S.D. Karam is supported by the NIDCR (R01 DE028529-01, R01 DE028282-01). We thank the University of Colorado Cancer Center Animal Imaging Shared Resources, Tissue Culture Core, Cytometry and Cell Sorting Shared Resource, Functional Genomics Facility and Biostatistics and Bioinformatics Share Resource supported by NCI P30CA046934 and CTSA UL1TR001082 Center grants. We thank Dr. A. Van Bokhoven at the Biorepository Core Facility, and personnel at the UC Brain Tumor Biorepository for providing de-identified human tissues. We thank Dr. D. Yu for providing breast cancer cells BT474m1 and BT474m1Br1, and Dr. P. Steeg for providing 231BR and JmT1BR3 cell lines.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 1, 2021; revised August 5, 2021; accepted September 16, 2021; published first September 20, 2021.

References

- Lee SS, Ahn J-H, Kim MK, Sym SJ, Gong G, Ahn SD, et al. Brain metastases in breast cancer: prognostic factors and management. *Breast Cancer Res Treat* 2008;111:523–30.
- Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Chambers AF, et al. Brain metastases of breast cancer. *Breast Dis* 2006;26:139–47.
- Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, et al. Limited overall survival in patients with brain metastases from triple-negative breast cancer. *Breast J* 2012;18:345–50.
- Barderas R, Bartolomé RA, Fernandez-Aceñero MJ, Torres S, Casal JI. High expression of IL-13 receptor α 2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. *Cancer Res* 2012;72:2780–90.
- Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. *Nature* 2009;459:1005–9.
- Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. *Am J Pathol* 2010; 176:2958–71.
- Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. *Nat Med* 2018;24:1024–35.
- Valiente M, Obenaus AC, Jin X, Chen Q, Zhang XH-F, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. *Cell* 2014;156:1002–16.
- Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. *Proc Natl Acad Sci U S A* 2014;111: 984–9.

10. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WEF, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. *Nat Med* 2010;16:116–22.
11. Christofori G. New signals from the invasive front. *Nature* 2006;441:444–50.
12. Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. *Mol Med* 2000;6:440–9.
13. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. *Cancer Res* 2000;60:1168–72.
14. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. *Clin Cancer Res* 2008;14:199–208.
15. Papageorgis P, Ozturk S, Lambert AW, Neophytou CM, Tzatsos A, Wong CK, et al. Targeting IL13R α 2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. *Breast Cancer Res* 2015;17:98.
16. Karnele EP, Pasricha TS, Ramalingam TR, Thompson RW, Gieseck RL, Knilans KJ, et al. Anti-IL-13R α 2 therapy promotes recovery in a murine model of inflammatory bowel disease. *Mucosal Immunol* 2019;12:1174–86.
17. Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee WK, et al. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. *Nat Commun* 2017;8:1913.
18. Chang K, Marran K, Valentine A, Hannon GJ. Creating an miR30-based shRNA vector. *Cold Spring Harb Protoc* 2013;2013:631–5.
19. Longo PA, Kavran JM, Kim MS, Leahy DJ. Single-cell cloning of a stable mammalian cell line. *Methods Enzymol* 2014;536:165–72.
20. Contreras-Zárate MJ, Day NL, Ormond DR, Borges VF, Tobet S, Gril B, et al. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases. *Oncogene* 2019;38:4685–99.
21. Eisemann T, Costa B, Strelau J, Mittelbronn M, Angel P, Peterziel H. An advanced glioma cell invasion assay based on organotypic brain slice cultures. *BMC Cancer* 2018;18:103.
22. Ferreira TA, Blackman AV, Oyrer J, Jayabal S, Chung AJ, Watt AJ, et al. Neuronal morphometry directly from bitmap images. *Nat Methods* 2014;11:982–4.
23. Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, et al. Estrogen promotes the brain metastatic colonization of triple-negative breast cancer cells via an astrocyte-mediated paracrine mechanism. *Oncogene* 2016;35:2881–92.
24. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. *JNCI J Natl Cancer Inst* 2008;100:1092–103.
25. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nat Methods* 2015;12:357–60.
26. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol* 2013;31:46–53.
27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
28. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 2010;28:511–5.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–50.
30. Kalli M, Mpekris F, Wong CK, Panagi M, Ozturk S, Thiagalingam S, et al. Activin a signaling regulates IL13R α 2 expression to promote breast cancer metastasis. *Front Oncol* 2019;9:32.
31. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. *In vivo* overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. *J Exp Med* 2001;194:1743–54.
32. Bartolomé RA, García-Palmero I, Torres S, López-Lucendo M, Balyasnikova IV, Casal JJ. IL13 receptor alpha2 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis. *Cancer Res* 2015;75:2434–44.
33. Vareslija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, et al. Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets. *J Natl Cancer Inst* 2019;111:388–98.
34. Lourenco AR, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, et al. Differential contributions of pre- and post-EMT tumor cells in breast cancer metastasis. *Cancer Res* 2020;80:163–9.
35. Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. *Cancer Microenviron* 2012;5:19–28.
36. Berghoff AS, Liao Y, Karreman MA, Ilhan-Mutlu A, Gunkel K, Sprick MR, et al. Identification and characterization of cancer cells that initiate metastases to the brain and other organs. *Mol Cancer Res* 2021;19:688–701.
37. Zhao JH, Reiske H, Guan JL. Regulation of the cell cycle by focal adhesion kinase. *J Cell Biol* 1998;143:1997–2008.
38. Pedanou VE, Gobeil S, Tabariès S, Simone TM, Zhu LJ, Siegel PM, et al. The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. *Elife* 2016;5:e16844.
39. Sun L, Yuan Y, Chen J, Ma C, Xu Y. Brahma related gene 1 (BRG1) regulates breast cancer cell migration and invasion by activating MUC1 transcription. *Biochem Biophys Res Commun* 2019;511:536–43.
40. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13R α 2 receptor is involved in induction of TGF- β 1 production and fibrosis. *Nat Med* 2006;12:99–106.
41. Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13R α 2. *Structure* 2010;18:332–42.
42. He CH, Lee CG, Dela Cruz CS, Lee C-M, Zhou Y, Ahangari F, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. *Cell Rep* 2013;4:830–41.
43. Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. *J Exp Med* 2003;197:703–9.
44. Park MH, Kwon HJ, Kim J-R, Lee B, Lee SJ, Bae YK. Elevated interleukin-13 receptor alpha 1 expression in tumor cells is associated with poor prognosis in patients with invasive breast cancer. *Ann Surg Oncol* 2017;24:3780–7.
45. Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda KA, Scott RJ, et al. Proteotranscriptomic profiling of 231-BR breast cancer cells: identification of potential biomarkers and therapeutic targets for brain metastasis. *Mol Cell Proteomics* 2015;14:2316–30.
46. Kandouz M. The Eph/Ephrin family in cancer metastasis: communication at the service of invasion. *Cancer Metastasis Rev* 2012;31:353–73.
47. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. *Nat Rev Cancer* 2010;10:165–80.
48. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. *Nat Cell Biol* 2000;2:62–69.
49. Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. *Annu Rev Pharmacol Toxicol* 2015;55:465–87.
50. Kania A, Klein R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. *Nat Rev Mol Cell Biol* 2016;17:240–56.
51. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. *Clin Cancer Res* 1995;1:1253–8.
52. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. *Mol Cancer Ther* 2006;5:3162–9.
53. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AKMG, Puntel M, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. *Proc Natl Acad Sci U S A* 2010;107:20021–6.
54. Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B, et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α 2. *J Biol Chem* 2012;287:30215–27.
55. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8⁺ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α -type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. *J Clin Oncol* 2011;29:330–6.
56. Sengupta S, Thaci B, Crawford AC, Sampath P. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. *Biomed Res Int* 2014;2014:952128.
57. Kahlon KS, Brown C, Cooper L, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. *Cancer Res* 2004;64:9160–6.
58. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. *N Engl J Med* 2016;375:2561–9.